Please login to the form below

Not currently logged in
Email:
Password:

insulin peglispro

This page shows the latest insulin peglispro news and features for those working in and with pharma, biotech and healthcare.

Lilly's Lantus 'follow-on' approved in the US

Lilly's Lantus 'follow-on' approved in the US

The settlement did not cover insulin glargine sold in vials or combination products. ... Approval is a boost to Lilly, which decided earlier this month to abandon development of another Lantus rival - insulin peglispro - after concluding data on a

Latest news

  • Lilly says insulin peglispro too risky to pursue Lilly says insulin peglispro too risky to pursue

    Discontinues development of medicine once tipped as a diabetes blockbuster.  . Eli Lilly has decided to discontinue development of insulin peglispro, a drug once considered a potential blockbuster for type 1 and ... Analysts have been divided on the

  • Novo Nordisk finally bags insulin degludec approval in US Novo Nordisk finally bags insulin degludec approval in US

    that the drug – along with Ryzodeg and Xultophy (insulin degludec/liraglutide) - achieved sales of just DKK601m ($90m) in the first six months of the year. ... However, there was some good news for Novo Nordisk when it emerged Eli Lilly had delayed

  • Rivals look to put pressure on Sanofi's Lantus Rivals look to put pressure on Sanofi's Lantus

    The company also released the results of five phase III studies of its long-acting insulin peglispro, which had a serious setback earlier this year when liver fat changes seen in ... However, some of the IMAGINE trials showed an increase in the liver

  • Sanofi wins European approval for Lantus follow-up Toujeo Sanofi wins European approval for Lantus follow-up Toujeo

    Long-acting insulin is a key part of the company's growth plans. ... However, the company will have slightly longer to establish Toujeo than it originally expected after regulatory filings for Lilly's insulin peglispro were delayed recently due to safety

  • FDA starts review of Novo's refiled diabetes pair FDA starts review of Novo's refiled diabetes pair

    Tresiba and Ryzodeg were rejected in 2013.  . The US FDA has started a fresh review of Novo Nordisk's long-acting insulin therapies Tresiba and Ryzodeg, which it turned down two ... Until recently, additional competition was also looming in the form of

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics